GlassScriptPhysician profile
Anant Desai
NPI 1871500389
$6,318.63
in general payments reported to CMS, 2019-2025
29 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $112 · 2021: $631 · 2022: $957 · 2023: $989 · 2024: $1,751 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,886 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.23 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $983.41 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $637.01 | 2021-2025 | Benlysta, Jesduvroq |
| Amgen INC. | $621.38 | 2023-2025 | Krystexxa, Tavneos, Epogen |
| Bayer Healthcare Pharmaceuticals INC. | $592.08 | 2021-2025 | |
| Akebia Therapeutics INC | $480.14 | 2024-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $365.50 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $349.50 | 2019-2024 | Ultomiris |
| Vifor Pharma, INC. | $341.49 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $289.74 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $268.49 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $244.42 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.83 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $185.47 | 2023-2025 | Tarpeyo |
| Pfizer INC. | $143.98 | 2019 | |
| Travere Therapeutics, INC. | $128.16 | 2022-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $116.67 | 2019 | |
| Mallinckrodt Hospital Products INC. | $98.67 | 2021-2024 | Acthar |
| Ardelyx, INC. | $95.06 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $79.14 | 2019-2024 | Jardiance, Mounjaro |
| Aurinia Pharma U.S., INC. | $50.38 | 2022-2023 | Lupkynis |
| Novo Nordisk INC | $18.27 | 2021 | |
| Exact Sciences Corporation | $15.84 | 2025 | Cologuard Collection Kit |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anant Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.